Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Oxford Ledge is still expanding full research coverage of CRBP. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Corbus develops cancer and obesity therapies, primarily advancing CRB-701, a Nectin-4-targeting antibody drug conjugate in clinical trials.
SEC filings
- 8-K Entry into material agreement; Regulation FD disclosure; Financial statements and exhibits 2026-07-06
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-05-26
- 8-K Entry into material agreement; Departure/election of directors or officers; Regulation FD disclosure; Financial statements and exhibits 2026-05-21
- 8-K Departure/election of directors or officers; Shareholder vote results; Regulation FD disclosure; Financial statements and exhibits 2026-05-14
- 10-Q Quarterly financial report (unaudited) 2026-05-12
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for CRBP. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open CRBP in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.